Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2

CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue. The anti-inflammatory COX2 inhibitor celecoxib has been utilized as anti-tumour drug...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Riva, Beatrice, Dominici, Marco De, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Salomoni, Paolo, Canonico, Pier Luigi, Genazzani, Armando A., Calabretta, Bruno, Condorelli, Fabrizio
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348412/
https://ncbi.nlm.nih.gov/pubmed/27835591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13146
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker